France Mammography Market Size

France Mammography Market Analysis

The France Mammography Market size is estimated at USD 109.67 million in 2024, and is expected to reach USD 167.5 million by 2029, growing at a CAGR of 8.84% during the forecast period (2024-2029).

The healthcare sector of France was adversely affected, as the demand decreased during the first wave of COVID-19 to keep hospitals and clinics free for COVID-19 patients and the risk of spreading the infection. Thus, all non-essential treatments and surgeries were postponed by healthcare institutions. Due to the panic created by the authorities across all social platforms, women were more than anxious about COVID-19 infection while getting their mammograms, which impacted the follow-up tests. In the initial months of the COVID-19 pandemic i.e. in April 2020, the diagnostic centers, magnetic resonance imaging laboratories, and X-ray clinics were forced to temporarily shut down to reorganize by the French government's new public health norms and guidelines. Although they eventually restarted, social distancing norms limited the number of patients at a particular time. However, during the year 2021, as the pandemic situation was in control, the elective breast cancer screenings started and the market was able to carry its momentum shortly. As per the article published by the National Institute of Health in October 2021 titled, 'Impact of the COVID-19 lockdown in France on the diagnosis and staging of breast cancers in a tertiary cancer center,' the COVID-19 lockout was associated with a 20% decline in breast cancer diagnoses. Breast tumors discovered after the lockdown had a worse outcome due to delayed diagnosis, larger tumor masses, and increased rates of nodal invasion. Hence, it is observed that the COVID pandemic had a significant impact on the market studied in France.

Being a developed country, France is witnessing higher adoption of the digital mamography systems. The growing research articles proving the efficacy of the technology is growing in the country creating the awareness of these systems and encouraging many facilities to adopt these advanced and accurate systems. For instance, Paolo Giorgi Rossi, in the article, 'Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk', published specifically for France in 2021, stated that breast density assessed with new fully automated method is positively associated with BC risk and is not inferior to radiologists' visual assessment. The study concludes that digital systems are efficient and no where any less than the physician assessment and eliminates the doubt form many patients who believe direct assessment is more efficient.

Hence, with the increasing significance of mammograms across the country, the market studied is expected to witness healthy growth over the forecast period.